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SUMMARY 
Classic polyarteritis nodosa (PAN) is a segmentary leucocytoclastic vasculitis that 
affects small- and medium-sized arteries. In 1931, Lindberg described the existence of a 
cutaneous variant of PAN, without visceral involvement and with a more favourable 
prognosis. We present four patients diagnosed with cutaneous PAN in our hospital 
between 1987 and 1998. The study group was composed of three women and one child, 
whose ages ranged from 11 to 70 years old. The follow-up period was between 2 and 13 
years. Each patient was submitted for an initial clinical, histological and laboratory 
evaluation and subsequent follow-up. The presence of nodules was the most frequent 
cutaneous lesion, preferentially located in the lower limbs. The erythrocyte 
sedimentation rate was the only parameter that was altered in all patients. Cutaneous 
biopsies from all patients showed a segmentary leucocytoclastic vasculitis in the arteries 
of the deep dermis and⁄or hypodermis. Direct immunofluorescence was positive in just 
one patient. No visceral involvement was found in any patient. There is confusion about 
the correct definition of cutaneous PAN. Some clinical findings, such as nodules or 
livedo reticularis, typical of cutaneous PAN suggest a good prognosis; however, we 
consider that it is necessary to evaluate these patients for systemic involvement for the 
possibility of arteritis in other organs as the term polyarteritis suggests. 
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Classic polyarteritis nodosa (PAN) is a segmentary leucocytoclastic vasculitis that 
affects small- and medium-sized arteries.1 Although any organ may be involved, those 
principally affected are the kidney, liver, heart or the gastrointestinal tract. If left 
untreated, the disease is fatal.2 In 1931, Lindberg described the existence of a cutaneous 
variant of PAN that was not associated with visceral symptoms and that presented a 
more favourable prognosis.3 Subsequently, many cases of cutaneous PAN have 
appeared in the literature confirming its benign character. 
In this paper we present four new cases of cutaneous PAN. As the result of a medium- 
and long-term study based on laboratory and clinical findings, we consider that the 
localized and benign nature of this disease was confirmed in each case. 
  
PATIENTS AND METHODS 
We have retrospectively reviewed the clinical and laboratory data obtained during the 
period between 1987 and 1998 from four patients diagnosed with cutaneous PAN. The 
patients included in this study all fulfilled the following criteria: cutaneous lesions 
typical of PAN (nodules, livedo, purpura) and cutaneous biopsies characterized by the 
presence of leucocytoclastic vasculitis of small- and medium-sized vessels. Moreover, 
no visceral complications were detected at the time of diagnosis nor during the 
evolution of the disease. The study group comprised three women and one child whose 
ages ranged from 11 to 70 years of age. The follow-up period was between 2 and 13 
years. Each patient was submitted for an initial clinical, histological and laboratory 
evaluation, and subsequent follow-up. 
  
RESULTS 
The most frequent cutaneous lesion in all patients was the presence of nodules with or 
without livedo reticularis (Fig. 1) and this was the first manifestation of the disease in 
all cases (Table 1). In patient 4 skin ulceration was also observed. In all cases, the 
cutaneous lesions were localized in the lower limbs, although patient 1 also had lesions 
in the arms. The paediatric patient developed several extracutaneous symptoms (Table 
1). In the adult group, patients 2 and 3 presented arthralgias, whereas patient 2 also 
presented occasional headache. Other related diseases such as chronic sinusitis (patient 
4) and recurrent tonsillitis (patient 1) were observed. In addition, patient 2 developed 
discoid lupus erythematous lesions several years after the diagnosis of PAN, although 
she did not fulfil the diagnostic criteria for systemic erythematous lupus established by 
the American Rheumatism Association. Other relevant findings are reflected in Table 1. 
The erythrocyte sedimentation rate (ESR) was the only parameter that was altered in 
nearly all patients (Table 2). In one patient a light haematuria was detected in an 
isolated analysis that was not confirmed in later analyses. Another patient registered an 
elevated antistreptolysin O antibody (ASO) titre that was probably related to a chronic 
tonsillitis. Serological tests for hepatitis B and C, brucella, syphilis and salmonella, and 
the tuberculin test were all negative when carried out (Table 2). 
Chest X-ray, electrocardiogram and abdominal ultrasonography, were normal in all 
patients. In patient 3, a renal angiogram was performed that did not show any 
alterations. Patient 2 presented irregularities in electromyograms showing a diminished 
response in the anterior tibial and quadriceps muscles. No alterations in either motor or 
sensorial conduction speeds were observed in the cases studied (Table 2). 
Deep incisional biopsies were obtained from all the patients, showing the presence of a 
segmentary leuco-cytoclastic vasculitis in the arteries of the deep dermis and⁄or 
hypodermis, with vascular occlusion in each case (Figs 2 and 3). Segmented fibrinous 
deposits that stained with fuchsin appeared at the wall of the damaged vessels. The 
inflammatory infiltrate was lymphocytic or of a lymphomacrophagic type with a smaller 
neutrophilic component. Direct immunofluorescence showed the presence of 
perivascular deposits of fibrinogen in only one case (patient 2). Granulomas were not 
observed. In patient 3, a dense interstitial inflammatory eosinophilic infiltrate was 
observed that was not associated with vascular damage. In all cases, the small vessels of 
the middle and upper dermis did not show any alterations. In addition, the presence of 
necrosis, both in the subcutaneous fat lobules and the epidermis were observed, 
probably as a result of ischaemia. No histological differences were found between 
biopsies from the adults and the child. 
Treatment was initially carried out with oral prednisone in nearly all patients at doses 
that varied between 20 and 60 mg daily. One of the adult patients was partially 
controlled with a dose of 20 mg daily and a decrease in the number of nodules was seen 
a few months after beginning the treatment (patient 2, Table 3). Another patient from 
this group required high doses of corticosteroids along with sulphone, finally achieving 
a disappearance of the lesions (patient 3, Table 3). Patient 4 presented persistent 
cutaneous lesions in spite of the treatment with prednisone and non-steroidal anti-
inflammatory drugs (NSAIDs). At the end of the study patient 3 is currently free of 
lesions without any treatment and patient 2 remains without lesions but continues under 
treatment with low doses of prednisone. The remaining patient is still treated with low 
doses of oral prednisone but in the continued presence of isolated cutaneous lesions. So 
far, no visceral involvement has been observed in any patient. The paediatric patient 
initially required the association of prednisone and cyclophosphamide to achieve 
response as well as various cycles of antibiotics for chronic tonsillitis. To date, he 
remains asymptomatic without treatment. 
 
DISCUSSION 
Cutaneous PAN is considered a localized form of PAN. Diagnosis requires the presence 
of cutaneous lesions typical of PAN (nodules, livedo, ulceration, purpura), the 
demonstration of a leucocytoclastic vasculitis in the arteries of the deep dermis or 
hypodermis, with or without associated fibrinoid necrosis; and the absence of visceral 
involvement at the time of diagnosis.1 The clinical manifestations are characterized by 
the presence of cutaneous nodules and livedo reticularis, mainly localized at the lower 
extremities.2 Other symptoms may be associated with cutaneous PAN, including 
constitutional symptoms, musculoskeletal and neurological symptoms, limited to the 
affected areas.1,4 The ESR is usually the only laboratory parameter altered in most of the 
patients with cutaneous PAN, as occurred in all our patients.2 In contrast, the typical 
cutaneous lesions in the systemic form are usually palpable purpura,2,5 and the presence 
of nodules, livedo, ulcers, necrosis or gangrene being rare. Systemic PAN is also often 
associated with vasculitis in other organs such as the kidney, liver, heart and the 
gastrointestinal tract.2 Characteristic findings in systemic PAN that differentiate it from 
the cutaneous form, are the presence of leucocytosis and eosinophilia, persistent 
proteinuria, high blood pressure, and diffuse neuromuscular involvement all giving rise 
to a poor short-term prognosis.6,7 Two of our patients diagnosed with cutaneous PAN 
had high blood pressure for 1–2 years before the appearance of the cutaneous lesions, 
which was being controlled by antihypertensive treatment. However, the diagnosis of 
arterial hypertension that is readily controlled and that does not have any repercussions 
in the retina, prior to the appearance of cutaneous lesions, is not indicative of systemic 
PAN.8
PAN is a rare disease in childhood.9 Although the systemic form is less favourable in 
children than in adults,10 the prognosis of cutaneous PAN is the same in childhood as it 
is in adults.2 The only child in our study presented many constitutional symptoms but 
showed a more favourable prognosis than the adults, as the cutaneous lesions 
disappeared after 2–3 years of treatment and he remained without them until the end of 
the time of study. 
Histopathological studies are necessary for the accurate diagnosis of this disease. A 
deep incisional biopsy, including subcutaneous tissue, is needed. The microscopic 
findings of cutaneous PAN can be divided into four stages: (i) degenerative stage with 
degeneration of arterial wall and deposition of fibrinoid material and partial or complete 
destruction of internal and external elastic laminae;11 (ii) acute inflammatory stage with 
an infiltrate mostly composed of neutrophils with some eosinophils around and within 
the arterial wall;6 (iii) granulation tissue stage with an infiltrate also containing 
lymphocytes and macrophages and intimal proliferation and thrombosis with occlusion 
of the lumen leading to ulceration; and (iv) healed end-stage with fibroblastic 
proliferation extending in the perivascular area.4,12 The small vessels of the middle and 
upper dermis may show only a non-specific lymphocytic perivascular infiltrate and 
focal panniculitis surrounding the involved artery may be present in contrast to the more 
diffuse form usually found in other nodular diseases. All of our patients were confirmed 
to have histological lesions of acute inflammatory and granulation tissue stages in their 
skin biopsies. With regard to direct immunofluorescence findings, the presence of IgM 
or C3 deposition in the vessel walls has been found in some patients, not only in the 
deep involved artery but also in the superficial and uninvolved small vessels.13,14 In this 
study, direct immunofluorescence was carried out in three patients and only one case 
showed the presence of perivascular fibrinogen. 
The aetiology of cutaneous PAN is unknown. Some authors think that immunological 
mechanisms might only participate in systemic vasculitides but not in cutaneous PAN.2 
Hepatitis viruses B and C have been implicated mainly in the pathogenesis of systemic 
PAN, and they have been associated with cutaneous PAN only in isolated cases.15,16 
Indeed, in our patients, serological tests for hepatitis B and C all proved negative when 
they were performed. Nevertheless, other infectious agents such as streptococcus could 
be implicated in some cases of cutaneous PAN and some authors recommend the 
systematic determination of the ASO titre in all patients with cutaneous PAN.2,10 In one 
of our patients we confirmed the presence of a raised ASO titre associated with a 
chronic tonsillitis that might support this hypothesis, although it is difficult to discard a 
casual relationship. Mycobacterium tuberculosis is another agent that has occasionally 
been implicated in cutaneous PAN.14 On the other hand, the presence of perinuclear 
antineutrophil cytoplasmic antibodies (P-ANCA) has been documented in some patients 
with systemic PAN,17 but also in isolated patients with cutaneous PAN.18,19 In our 
patients the analysis of ANCA was negative when it was done. Thus, although the 
relationship of ANCA with classical PAN is not clear, it appears that patients with both 
large and small vessel arteritis are sometimes P-ANCA or cytoplasmic-ANCA positive, 
whereas those with exclusively large vessel arteritis are generally ANCA negative.20
Cutaneous PAN does not require the intense treatment to bring about remission that is 
necessary for systemic PAN. Because of the benign course of the cutaneous form, a 
conservative therapeutic plan should be followed. Although there are no doubleblind 
prospective placebo-controlled trials for therapy, treatment could be initiated with low 
doses of sulphapyridine, NSAIDs or salicylate, that may induce remission or relieve the 
symptoms or signs of the disease.21 Antibiotic treatment may be needed in patients with 
documented streptococcal or other bacterial infections.2 If there is no response, low or 
moderate doses of corticosteroids or weekly methotrexate have been used with good 
responses.22
In the light of these findings, we consider that most of the patients with cutaneous PAN 
are associated with a good prognosis. We should keep in mind that the presence of some 
extracutaneous symptoms such as constitutional symptoms, local neurological and mus-
culoskeletal manifestations, may also be associated with cutaneous PAN without 
indicating its evolution to systemic PAN. However, as cutaneous involvement may also 
occur in 20–30% of cases of systemic PAN2 and there are cutaneous forms that have 
aneurysms in renal angiogram,23 perhaps we can consider that the spectrum of PAN is 
depicted as a disease continuum ranging from skin disease alone to life-threatening 
systemic disease, the same as cutaneous and systemic lupus erythematosus.21 We think 
that is very important to check these patients carefully to exclude systemic involvement, 
not only in the first visit but also in a continuous follow-up (Table 4). 
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Table 1. Clinical symptoms and related diseases 
 Patient 1 Patient 2 Patient 3 Patient 4 
Age at diagnosis (years) 11 39 44 70 
Sex M F F F 
Time of follow-up (years) 13 3 5 2 
Nodules + + + + 
Livedo reticularis + – + + 
Purpura – – – – 
Ulcers – – – + 
Legs involvement + + + + 
Arms involvement + – – – 
Another location – – – – 
Fever + – – – 
Asthenia + – – – 
Abdominal pain + – – – 
Arthralgia + + + – 
Headache + + – – 
Paraesthesias Feet – – – 
 Hand – – – 
Myalgia – – – – 
Related diseases CT DLE CG CS 
Arterial hypertension – + – + 
+, symptom present; –, symptom absent; CT, chronic tonsillitis; DLE, 
discoid lupus erythematous; CG, chronic gastritis; CS, chronic 











Table 2. Laboratory results and complementary explorations 
 Patient 1 Patient 2 Patient 3 Patient 4 
Full blood count N N N N 
ESR 52 ⁄ 90 102 ⁄ 118 9 ⁄ 22 ND 
Urinalysis Haematuria N ND N 
Creatinine N N N N 
Liver function tests N N N N 
ASO (UI) ↑↑↑ N ND ND 
Complement N ND N N 
ANA – – – – 
ANCA ND ND – – 
RF – – – – 
Cryoglobulins ND – – ND 
Tuberculin – – – ND 
HB antibodies ND ND antiHbs ND 
HC antibodies – ND – – 
EMG N Response ↓ N ND 
Conduction speeds N N N ND 
Renal angiogram ND ND N ND 
N, normal; ND, not done; –, negative; ANA, antinuclear antibodies; ANCA, 
antineutrophil cytoplasm antibodies; antiHbs, anti-hepatitis B surface antigen; ASO, 
antistreptolysin O; EMG, electromyogram; ESR, erythrocyte sedimentation rate; HB, 




Table 3. Treatment and prognosis 
 Patient 1 Patient 2 Patient 3 Patient 4 
Treatment P + C + A P P + S P + NSAID     
Present clinical situation NL NL NL WL 
Visceral involvement – – – – 
Present treatment No P No P 
P, prednisone; C, cyclophosphamide; A, antibiotics; S, sulphone; NSAID, non-steroid 
anti-inflammatory drugs; NL, no lesions; WL, with cutaneous lesions; –, without 
visceral involvement 
 
Table 4. Initial evaluation and follow-up 
First visit 
Evaluation for systemic 
involvement 
Anamnesis and complete physical examination 
(collaboration with internal medicine 
physician or paediatrician). Arterial pressure. 
 
Full blood count, ESR, liver and renal function 
tests, cryoglobulins, ANA, ANCA, RF and 
complement. 
 If paraesthesias: neural conduction speeds. 
 
If high pressure or renal dysfunction: renal 
angiogram. 
 
If abdominal pain: blood in stool, colonoscopy 
or mesenteric arteriography. 
 
If myalgias or muscle weakness: 
electromyogram and muscle enzymes. 
Evaluation for aetiology 
Anamnesis (drugs, infections, other diseases) 
and complete physical examination. 
 
ASLO, tuberculin and virus hepatitis B and C 
serology. 
Follow-up (every 6–12 months) 
 
If patient is asymptomatic: anamnesis and 
complete physical examination. Arterial 
pressure. 
 
Full blood count, ESR, complement, liver and 
renal function tests. 
 If symptoms (as shown above). 
ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies; ANCA, 






























 Figure 2. Segmentary effects in a medium-sized artery. Note the presence of fibrinogen 
deposits that stain with fuchsin (Masson’s trichromate, original magnification x 100). 
 
 
Figure 3. Transverse section of a cutaneous medium-sized artery that shows an intense 
lymphomacrophage infiltration of the vessel’s wall causing vascular distortion and 
occlusion of the light (haematoxylin and eosin, original magnification x 200). 
